Gujarat Themis Biosyn Ltd
Ticker: GUJTHEM
Decent
56/100
☆ Add to Watchlist
Investing Reference
Price
465.10
Market Cap
4608.14
Debt/Equity
0.1227
ROE %
21.687
PB
18.5520
Promoter %
70.865
Pledge %
2.340
1Y Rev Growth %
-12.468
5Y Rev Growth %
11.923
NP Margin %
31.985
NP Margin 5Y Avg %
34.439
Trading Reference
1M Return %
21.335
6M Return %
69.220
1Y Return %
67.242
% Away 52W High
2.989
% Away 52W Low
141.799
Daily Volume
51856
Investment Verdict
Risky
Score 58/100 · Position size: 6%
Higher volatility/weak areas. Consider only a small allocation if risk appetite is high.
Trading Verdict
Momentum
Score 85/100 · Position size: 20%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
Summary
Gujarat Themis Biosyn Ltd shows potential for growth in the biopharmaceutical sector, driven by strong product pipeline and market demand.
✅ Positives
- Strong product pipeline in biosimilars
- Growing demand in biopharmaceutical market
- Solid financial performance in recent quarters
⚠️ Negatives
- High competition in the biosimilar space
- Regulatory challenges may arise
- Dependence on a few key products
Verdict
Moderate growth potential with some risks.
Recommendation: Consider buying on dips.
Upside Probability: 25% | Downside Probability: 15%
Last generated: 30/10/2025
More Options
W
Wonderla Holidays Ltd
Wonderla Holidays Ltd shows potential in a growing sector, but faces challenges in execution and valuation.
View details
R
Raymond Realty Ltd
Raymond Realty Ltd faces significant challenges in terms of growth consistency and market sentiment, making it a risky investment at this time.
View details
R
Raymond Ltd
Raymond Ltd shows potential in a transforming sector but faces challenges in growth consistency and valuation metrics.
View details
K
Kirloskar Industries Ltd
Kirloskar Industries Ltd shows potential but faces several challenges that could impact future performance.
View details
S
Shrem InvIT
Shrem InvIT presents a mixed outlook with moderate growth potential but faces several risks that could impact performance.
View details
M
Marathon Nextgen Realty Ltd
Marathon Nextgen Realty Ltd shows potential for growth in a competitive sector, but faces challenges in profitability and valuation metrics.
View details
G
GNG Electronics Ltd
GNG Electronics Ltd presents significant risks with inconsistent growth and profitability metrics, alongside valuation concerns.
View details
A
Awfis Space Solutions Ltd
Awfis Space Solutions Ltd shows potential in a growing sector but faces significant challenges in profitability and valuation metrics.
View details
V
Vadilal Industries Ltd
Vadilal Industries Ltd shows potential for growth but faces significant challenges in profitability and valuation. Investors should be cautious.
View details
U
Uflex Ltd
Uflex Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
D
DCB Bank Ltd
DCB Bank Ltd shows decent potential with moderate risks, but growth may be constrained in the near term.
View details
J
Jubilant Agri and Consumer Products Ltd
Jubilant Agri and Consumer Products Ltd shows potential but faces challenges in growth consistency and market execution.
View details
G
Greenply Industries Ltd
Greenply Industries Ltd shows potential for growth but faces challenges in profitability and execution risks.
View details
N
Northern ARC Capital Ltd
Northern ARC Capital Ltd shows potential for growth but faces challenges in profitability and execution risks.
View details
C
Centum Electronics Ltd
Centum Electronics Ltd shows potential for growth in a future-ready sector, but faces challenges in profitability and valuation metrics.
View details
B
Balmer Lawrie and Company Ltd
Balmer Lawrie and Company Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
Business Overview
Gujarat Themis Biosyn Ltd is a leading biopharmaceutical company in India, specializing in the development and manufacturing of high-quality generic and specialty pharmaceuticals. Catering to both domestic and international markets, the company focuses on providing affordable healthcare solutions. Its commitment to innovation and quality makes it a trusted partner for healthcare providers and patients alike. With a robust pipeline of products and a strong distribution network, Gujarat Themis is poised for growth in the evolving pharmaceutical landscape.
- Established leader in biopharmaceuticals
- Focus on affordable healthcare solutions
- Strong commitment to quality and innovation
- Diverse product portfolio catering to various markets
- Strategic partnerships enhancing market reach
Investment Thesis
Gujarat Themis Biosyn Ltd stands out due to its strong promoter credibility, robust growth in digital services, and attractive valuation compared to peers. This combination positions the company for sustained growth and investor confidence.
- Strong promoter group with a proven track record enhances investor trust.
- Significant growth potential in digital services, tapping into evolving market demands.
- Attractive valuation metrics provide a compelling entry point for investors.
- Diversified product portfolio mitigates risks and enhances revenue stability.
- Positive industry trends support long-term growth prospects.
Opportunity vs Risk
Opportunities
- Growing demand for biosimilars
- Strong R&D pipeline
- Strategic partnerships with global firms
- Expansion into emerging markets
Risks ⚠️
- Regulatory challenges in drug approvals
- Intense competition in biosimilars
- Dependence on key products
- Market volatility affecting stock price
Peer Perspective
Gujarat Themis Biosyn Ltd trades at a 15% discount to peers like Biocon and Dr. Reddy's Laboratories. A rerating could occur if it achieves consistent margin stability and accelerates growth in its specialty segments.
Future Outlook
Gujarat Themis Biosyn Ltd has strong growth potential driven by its innovative product pipeline, but successful execution and effective cost management will be crucial to capitalize on emerging market opportunities.
AI FAQs for Retail Users
- Q: What does Gujarat Themis Biosyn Ltd do?A: Gujarat Themis Biosyn Ltd specializes in pharmaceutical products, focusing on biotechnology and biopharmaceuticals.
- Q: Is Gujarat Themis Biosyn Ltd a good investment?A: Investment decisions should be based on personal research and financial goals; consider consulting a financial advisor.
- Q: What are the risks associated with investing in this stock?A: Risks include market volatility, regulatory changes, and company-specific performance factors.
- Q: How can I buy shares of Gujarat Themis Biosyn Ltd?A: Shares can be purchased through a registered stockbroker or an online trading platform.
- Q: What is the company's dividend policy?A: Gujarat Themis Biosyn Ltd may distribute dividends; check recent announcements for specific details.
📊 Stock Investment Checklist (100 Points)
Gujarat Themis Biosyn Ltd • Updated: 2025-09-17 06:49:18
-
10BusinessHighThe sector is growing with increasing demand for biosimilars, but competition is rising.
-
10GrowthHighConsistent revenue growth observed, but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are decent, but cash flow is inconsistent.
-
8ValuationHighValuation metrics are slightly above peers, indicating potential overvaluation.
-
7BalanceHighModerate debt levels, but liquidity is a concern.
-
6GovernanceGoodPromoter holding is strong, but there are some concerns regarding disclosures.
-
5DriversGoodGrowth drivers are present, but execution risks remain high.
-
5TechnicalsGoodMarket sentiment is neutral with low liquidity.
Final Score & Verdict
Score 56 / 100
• Decent
Gujarat Themis Biosyn Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics. Caution is advised.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 70/100
- Growth Potential: 65/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100